FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL             |           |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number:              | 3235-0104 |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response:      | 0.5       |  |  |  |  |  |  |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>LEVIN MARK J</u>   | 2. Date of Eve<br>Requiring Stat<br>(Month/Day/Ye<br>02/05/2014 | ement              | 3. Issuer Name and Ticker or Trading Symbol Eleven Biotherapeutics, Inc. [ EBIO ]           |                                  |                                    |  |   |  |  |  |
|--|---|--------------------|---|----------------------------------|------------------------------------|--|---|--|--|--|
| (Last) (First) (Middle) 215 FIRST STREET, SUITE 400  | _   02/03/2014  |                    | Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner |                                  |                                    | 5. If Amendment, Date of Original Filed (Month/Day/Year) |   |  |  |  |
|  |   |                    | Officer (give title   | Other (spec                      | cify 6. In                         | dividual or Joint<br>icable Line)                        | /Group Filing (Check  |  |  |  |
| (Street) CAMBRIDGE MA 02142  |   |                    | below)  | below)                           | X                                  | Form filed by  | y One Reporting Person<br>y More than One<br>erson          |  |  |  |
| (City) (State) (Zip)   |   |                    |   |                                  |                                    |  |   |  |  |  |
| Table I - Non-Derivative Securities Beneficially Owned   |   |                    |   |                                  |                                    |  |   |  |  |  |
| 1. Title of Security (Instr. 4)  |   |                    | 2. Amount of Securities<br>Beneficially Owned (Instr. 4)                                    |                                  |                                    | . Nature of Indirect Beneficial Ownership<br>nstr. 5)    |   |  |  |  |
| Common Stock   |   |                    | 330,708   | I                                | See footnote. <sup>(1)</sup>       |  |   |  |  |  |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |                    |   |                                  |                                    |  |   |  |  |  |
| 1. Title of Derivative Security (Instr. 4)   | 2. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)  |                    | 3. Title and Amount of Securities<br>Underlying Derivative Security (Instr. 4)              |                                  | 4.<br>Conversion<br>or Exercise    | 5.<br>Ownership<br>Form:                                 | 6. Nature of Indirect<br>Beneficial Ownership<br>(Instr. 5) |  |  |  |
|  | Date<br>Exercisable   | Expiration<br>Date | Title   | Amount or<br>Number of<br>Shares | Price of<br>Derivative<br>Security | Direct (D)<br>or Indirect<br>(I) (Instr. 5)              |   |  |  |  |
| Series A Preferred Stock   | (2)   | (2)                | Common Stock  | 3,267,716                        | (2)                                | I  | See footnote.(1)  |  |  |  |
| Series B Preferred Stock   | (3)   | (3)                | Common Stock  | 481,619                          | (3)                                | I  | See footnote.(1)  |  |  |  |
| Common Stock Warrant (right to purchase)   | (4)   | (4)                | Common Stock  | 127,077                          | 0.0635                             | I  | See footnote.(1)  |  |  |  |
| Common Stock Warrant (right to purchase)   | (5)   | (5)                | Common Stock  | 82,989                           | 0.0635                             | I  | See footnote. <sup>(1)</sup>                                |  |  |  |

## **Explanation of Responses:**

- 1. The securities are directly held by Third Rock Ventures, L.P. ("TRV LP"). The general partner of TRV LP is Third Rock Ventures GP, LP ("TRV GP"). The general partner of TRV GP is Third Rock Ventures GP, LLC ("TRV LLC"). The Reporting Person is a manager of TRV LLC and disclaims beneficial ownership of all shares except to the extent of his pecuniary interest, if any, therein.
- 2. The Series A Preferred Stock is convertible into Common Stock on an 6.35-for-one basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- 3. The Series B Preferred Stock is convertible into Common Stock on an 6.35-for-one basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election, and automatically upon the closing of the Issuer's initial public offering, and has no expiration date.
- 4. The Warrant to purchase Common Stock as shown in column 3 is exercisable at any time at the holder's election prior to June 28, 2018, and automatically upon the closing of the Issuer's initial public offering.
- 5. The Warrant to purchase Common Stock as shown in column 3 is exercisable at any time at the holder's election prior to December 4, 2018, and automatically upon the closing of the Issuer's initial public offering.

## Remarks:

<u>/s/ Mark J. Levin</u>

\*\* Signature of Reporting Person Date

02/06/2014

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.